Trigeminal neuralgia (TN), also known as tic douloureux, is a chronic pain disorder that affects the fifth cranial or trigeminal nerve. It causes inflammatory conditions due to systemic diseases including Lyme disease, sarcoidosis, and multiple sclerosis. There is also an association with collagen vascular diseases including systemic lupus erythematosus and scleroderma. The condition is treated on an outpatient basis, except till neurosurgical intervention is required. Its management must be customized individually, based on the patient's general condition and age. However, the exact cause of the condition is unknown.
Trigeminal neuralgia treatment market can be subdivided into drug therapy and surgery. Trigeminal neuralgia surgery is undertaken if medication causes troublesome side-effects or does not work. There are three main types of surgeries, rhizotomy, stereotactic radiosurgery and microvascular decompression. Rhizotomy is an outpatient procedure performed under general anesthesia. It involves destroying the fibers within the trigeminal nerve that are carrying pain signals. Microvascular decompression is the most curative and permanent surgery for trigeminal neuralgia treatment. It is usually offered to patients who are not too older and are in reasonably good health.
Idiopathic trigeminal neuralgia, for which cause is unknown, is mostly treated with a single anticonvulsant medication such as carbamazepine. Carbamazepine, oxcarbazepine, gabapentin, lamotrigine or baclofen are some drugs used in treatment of TN. Carbamazepine often works well for trigeminal neuralgia and can ease symptoms of TN within 1-2 days. Its dose varies from patient to patient. Other medicines that ease nerve impulses can be used in combination of two drugs if one alone does not help. However, these medicines can cause various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness. Moreover, these drugs lose their effectiveness with time, requiring greater number of medications or higher doses taken together. Some patients experience side effects serious enough to discontinue the medication. Furthermore, some issues about diagnosis, surgical and pharmacological treatment of TN are unsettled. Major issues to address in the management of patients with TN include persistent side effects from medication, continued delays in diagnosis, and a lack of psychological support. All these factors are expected to hinder growth of the market during the forecast period. However, the European Federation of Neurological Societies and the American Academy of Neurology launched a combined task force to prepare general guidelines for the management of trigeminal neuralgia.
Increasing number of geriatric population is expected to drive growth of the trigeminal neuralgia treatment market worldwide as elderly people are more prone to get affected. Trigeminal neuralgia majorly affects people with age of 50 or more. It can occur at any age, including infancy. Young adults suffering from multiple sclerosis have high risk of developing TN. According to national Institute of Neurological Disorders and Stroke (NINDS), the number of new cases is around 12 per 100,000 each year. The condition is more common among women than in men. In young individuals, the cause is mostly idiopathic, but as compared to elderly, adult cases are mostly caused due to central nervous system damage similar to individuals with multiple sclerosis. The condition is extremely rare in children. However, various side effects such as amnesia, nausea, drowsiness, dizziness, and unsteadiness caused due to medications can negatively impact growth of the market. Furthermore, these drugs lose their efficacy over time.
Regional segmentation of trigeminal neuralgia market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America trigeminal neuralgia treatment market is expected to hold a significant position due to increasing awareness among people about the condition. The Facial Pain Research Foundation and Intl Trigeminal Neuralgia and Me organized the International Trigeminal Neuralgia Awareness Day on October 7th every year. The market in Asia Pacific region is expected to grow at lucrative rate, owing to large number of population. According to a study published by Omics International, in China an estimated 4,458,090 people that is 2.6% among the total population are suffering from this condition. Market in emerging economies offer opportunities to market players in trigeminal neuralgia treatment market.
Major players operating in the trigeminal neuralgia treatment market include Allergan Plc, Merz Pharma GmbH & Co., Biogen, Inc., Merz Pharma GmbH & Co., Abbott Laboratories, Trigemina Inc., Pfizer Inc., Novartis, and GlaxoSmithKline Plc. Few industry player focus on developing technologically advanced products that eliminate the need for drugs and surgery in acute pain occurred due to TN. For instance, The PainShield (NanoVibronix) transmits slow release ultrasound to deliver fast pain relief for nerve and soft tissue damage. It is extremely effective and provides trigeminal neuralgia acute pain relief and treatment.